Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Net Cash Flow (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Net Cash Flow over the past 16 years, most recently at $2.8 million for Q2 2025.

  • Quarterly results put Net Cash Flow at $2.8 million for Q2 2025, down 47.15% from a year ago — trailing twelve months through May 2025 was -$197000.0 (up 98.15% YoY), and the annual figure for FY2025 was -$197000.0, up 98.15%.
  • Net Cash Flow for Q2 2025 was $2.8 million at Lifecore Biomedical, Inc. \De\, up from -$4.0 million in the prior quarter.
  • Over the last five years, Net Cash Flow for LFCR hit a ceiling of $16.1 million in Q2 2023 and a floor of -$10.4 million in Q3 2023.
  • Median Net Cash Flow over the past 5 years was $2000.0 (2021), compared with a mean of $647833.3.
  • Biggest five-year swings in Net Cash Flow: surged 7749.76% in 2023 and later crashed 2628.38% in 2025.
  • Lifecore Biomedical, Inc. \De\'s Net Cash Flow stood at -$356000.0 in 2021, then surged by 832.58% to $2.6 million in 2022, then tumbled by 307.86% to -$5.4 million in 2023, then surged by 172.59% to $3.9 million in 2024, then fell by 27.62% to $2.8 million in 2025.
  • The last three reported values for Net Cash Flow were $2.8 million (Q2 2025), -$4.0 million (Q1 2025), and $3.9 million (Q4 2024) per Business Quant data.